ReviewFrontiers in bioengineering and biotechnology2024
Research and application of intelligent diagnosis and treatment engineering bacteria.
Review in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For over a century, scientists have been harnessing the therapeutic potential of bacteria in treating diseases. The advent of synthetic biology in recent years has propelled the development of genetically engineered bacteria with enhanced intelligence. These bacteria can autonomously detect environmental cues and relay them to pivotal promoters, leading to the expression of functional proteins. By utilizing modular components, they are capable of executing a range of functions, including sensing, transmitting, and outputting signals. Based on these principles, a series of intelligent diagnostic and therapeutic engineered bacteria have emerged. These bacteria are capable of targeting diseased sites, sensing disease-specific signals, and producing reporter and therapeutic drugs. Furthermore, the integration of intelligent diagnostic and therapeutic engineered bacteria with advanced technologies such as artificial intelligence, nanomaterials, and optics has paved the way for diverse clinical applications. Three critical stages are explored in this article, which include the selection of strains, the design of biosensing systems, and the planning of release strategies. The application of intelligent diagnosis and treatment engineering bacteria in metabolic diseases, inflammatory diseases, tumors and infectious diseases is reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.